Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III – V)

Bibliography

• US Renal Data System. USRDS 2008 Annual Data Report. Chapter 11: Costs of end-stage renal disease. Available from: http://www.usrds.org/2008/pdf/V2_11_2008.pdf [Last accessed 30 September 2010]
   Google Scholar
• USRDS. Excerpts from the United States Renal Data System 1998 Annual Data Report. Incidence and prevalence of ESRD. Am J Kidney Dis 1998;32:S38-49
   Google Scholar
• Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Re-assessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non traditional risk factors. J Am Soc Nephrol 1997;8:475-86
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-19
   Google Scholar
• US Renal Data System. USRDS 2000 Annual Report National Institutes of Health, Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases
   Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium – phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17
   PubMed Web of Science ®Google Scholar
• Tentori F, Blayney MJ, Albert JM, Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
   PubMed Web of Science ®Google Scholar
• Young EW, Akiba T, Albert JM, Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:34-8
   PubMed Web of Science ®Google Scholar
• Calvo MS, Park YK. Changing phosphorus content of the US diet: potential for adverse effects on bone. J Nutr 1996;126(Suppl 4):1168-80
   Google Scholar
• Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 2004;65:1-14
   PubMed Web of Science ®Google Scholar
• Birge SJ, Miller R. The role of phosphate in the action of vitamin D on the intestine. J Clin Invest 1977;60:980-8
   PubMedGoogle Scholar
• Hattenhauer O, Traebert M, Murer H, Biber JK. Regulation of small intestinal Na-P(i) type IIb cotransporter by dietary phosphate intake. Am J Physiol 1999;277(4 Pt 1):G756-62
   Google Scholar
• Xu H, Bai L, Collins JF, Ghishan FK. Age-dependent regulation of rat intestinal type IIb sodium-phosphate cotransporter by 1,25-(OH)(2) vitamin D(3). Am J Physiol Cell Physiol 2002;282:C487-93
   Google Scholar
• Fleet JC, Bruns ME, Hock JM, Wood RJ. Growth hormone and parathyroid hormone stimulate intestinal calcium absorption in aged female rats. Endocrinology 1994;134:1755-60
   PubMed Web of Science ®Google Scholar
• Kaplan RA, Haussler MR, Deftos LJ, The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest 1977;59:756-60
   PubMed Web of Science ®Google Scholar
• Nemere I, Larsson D. Does PTH have a direct effect on intestine? J Cell Biochem 2002;86:29-34
   PubMed Web of Science ®Google Scholar
• Levin A, Bakris GL, Molitch M, Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8
   PubMed Web of Science ®Google Scholar
• Vassalotti JA, Uribarri J, Chen SC, ; Kidney Early Evaluation Program Investigators. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999 – 2004. Am J Kidney Dis 2008;51(Suppl 2):S56-68
   Google Scholar
• Gutierrez O, Isakova T, Rhee E, Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-15
   PubMed Web of Science ®Google Scholar
• Fliser D, Kollerits B, Neyer U, ; MMKD Study Group. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007;18:2600-8
   PubMed Web of Science ®Google Scholar
• Titan SM, Zatz R, Jorgetti V, Moyses RMA. FGF23 as predictor of renal outcome in diabetic nephropathy. Presented at the American Society for Nephrology 2009 Meeting, Poster F-PO1872; 16 – 21 November 2009; Denver, USA
   Google Scholar
• Ketteler M, Schlieper G, Floege J. Hypertension calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 2006;47:1027-34
   PubMed Web of Science ®Google Scholar
• Li XL, Yang HY, Giachelli CM. Role of sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006;98:905-12
   PubMed Web of Science ®Google Scholar
• Hunt J, Fairman R, Mitchell M, Bone formation in carotid plaques a clinicopathological study. Stroke 2002;33:1214-19
   PubMed Web of Science ®Google Scholar
• London G, Guerin A, Marchais S, Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-40
   PubMed Web of Science ®Google Scholar
• Damjanovic T, Djuric S, Schlieper G, Clinical features of hemodialysis patients with intimal versus medial vascular calcifications. J Nephrol 2009;22:358-66
   PubMed Web of Science ®Google Scholar
• Guerin AP, Blacher J, Pannier B, Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987-92
   PubMed Web of Science ®Google Scholar
• Stevens LA, Djurdjev O, Cardew S, Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004;15:770-9
   PubMed Web of Science ®Google Scholar
• Blacher J, Guerin AP, Pannier B, Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-42
   PubMed Web of Science ®Google Scholar
• Wang AY, Wang M, Woo J, Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003;14:159-68
   PubMed Web of Science ®Google Scholar
• Leggat Jr JE, Orzol SM, Hulbert-Shearon TE, Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis 1998;32:139-45
   PubMedGoogle Scholar
• Young EW, Albert JM, Satayathum S, Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns study. Kidney Int 2005;67:1179-87
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kuwae N, Regidor DL, Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-80
   PubMed Web of Science ®Google Scholar
• Kestenbaum B, Sampson JN, Rudser KD, Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-8
   PubMed Web of Science ®Google Scholar
• Tonelli M, Sacks F, Pfeffer M, ; Cholesterol and Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-33
   PubMed Web of Science ®Google Scholar
• Dhingra R, Sullivan LM, Fox CS, Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-85
   PubMed Web of Science ®Google Scholar
• Young EW, Akibia T, Albert J, Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patters Study (DOPPS). Am J Kidney Dis 2004;44(5 Suppl 2):S34-8
   PubMedGoogle Scholar
• Qunibi WY, Nolan CR. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study. Kidney Int 2004;90(Suppl):S33-8
   Google Scholar
• Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003;14(9 Suppl 4):S300-4
   Google Scholar
• Sigrist M, Bungay P, Taal MW, McIntyre CW. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant 2006;21:707-14
   PubMed Web of Science ®Google Scholar
• Moe SM. Uremic vasculopathy. Semin Nephrol 2004;24:413-16
   PubMedGoogle Scholar
• Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004;95:560-7
   PubMed Web of Science ®Google Scholar
• Jono S, McKee MD, Murry CE, Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-17
   PubMed Web of Science ®Google Scholar
• Zucchelli P, Santoro A. Inorganic phosphate removal during different dialytic procedures. Int J Artif Organs 1987;10:173-8
   PubMedGoogle Scholar
• Charra B, Chazot C, Jean G, Long 3 × 8 hr dialysis: a three-decade summary. J Nephrol 2003;16(Suppl 7):S64-9
   Google Scholar
• Locatelli F, Buoncristiani U, Canaud B, Dialysis dose and frequency. Nephrol Dial Transplant 2005;20:285-96
   PubMed Web of Science ®Google Scholar
• Antharaman P, Moss AH. Should the medicare ESRD program pay for daily dialysis. an ethical analysis. Adv Chronic Kidney Dis 2007;14:290-6
   PubMedGoogle Scholar
• Finn WF, Joy MS, Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004;62:193-201
   PubMed Web of Science ®Google Scholar
• Spasovski GB, Sikole A, Gelev S, Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006;21:2217-447
   PubMed Web of Science ®Google Scholar
• Sheikh MS, Maguire JA, Emmett M, Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989;83:66-73
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) website. Available from: http://www.KDIGO.ORG [Last accessed 30 September 2010]
   Google Scholar
• K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease. Am J Kidney Dis 2003;42(4 Suppl 3):S1-201
   Google Scholar
• Moe SM, Drueke TB, Block GA, ; for CKD Workgroup. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76(Suppl 113):S50-99
   Google Scholar
• Manns B, Klarenbach S, Lee H, Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007;22:2867-78
   PubMed Web of Science ®Google Scholar
• Uhlig K, Berns J, Kestenbaum B, KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD–Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010;55:773-99
   PubMed Web of Science ®Google Scholar
• Locatelli F, Cannata-Andia J, Drueke T, Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002;17:723-31
   PubMed Web of Science ®Google Scholar
• Shantouf R, Ahmadi N, Flores F, Impact of phosphate binder type on coronary artery calcification in hemodialysis patients. Clin Nephrol 2010;74:12-8
   PubMed Web of Science ®Google Scholar
• Alfrey AC. Aluminum intoxication. N Engl J Med 1984;310:1113-15
   PubMed Web of Science ®Google Scholar
• Spasovski GB, Sikole A, Gelev S, Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006;21:2217-447
   PubMed Web of Science ®Google Scholar
• D'Haese PC, Spasovski GB, Sikole A, A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003;85(Suppl):S73-78
   Google Scholar
• Hutchison AJ. Oral phosphate binders. Kidney Int 2009;75:906-14
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
   PubMed Web of Science ®Google Scholar
• Ferramosca E, Burke S, Chasan-Taber S, Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005;149:820-5
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium-phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14:2907-14
   PubMed Web of Science ®Google Scholar
• Bleyer AJ, Burke SK, Dillon MM, A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33:694-701
   PubMed Web of Science ®Google Scholar
• Slatopolsky EA, Burke SK, Dillon MA. RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone: the RenaGel Study Group. Kidney Int 1999;55:299-307
   PubMed Web of Science ®Google Scholar
• Sprague S. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer and lanthanum carbonate. Curr Med Res Opin 2007;23:3167-75
   PubMed Web of Science ®Google Scholar
• Sonikian MA, Pani IT, Iliopoulos AN, Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005;27:143-7
   PubMed Web of Science ®Google Scholar
• Vlahakos D, Retsa K, Kalogeropoulou S, Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study. Artif Organs 2007;31:892-5
   PubMed Web of Science ®Google Scholar
• De Santo N, Frangiosa A, Anastasio P, Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006;19(Suppl 9):S108-14
   PubMedGoogle Scholar
• Oka Y, Miyazaki M, Takatsu S, Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. Ther Apher Dial 2007;11:107-13
   PubMed Web of Science ®Google Scholar
• Brezina B, Qunibi Nolan C. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int 2004;66:S39-45
   Google Scholar
• Duggal A, Hanus M, Zhorov E, Novel dosage forms and regimens for sevelamer based phosphate binders. J Ren Nutr 2006;16:248-52
   PubMedGoogle Scholar
• Fan S, Ross C, Mitra S, A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 2009;24:3794-9
   PubMed Web of Science ®Google Scholar
• Plone MA, Petersen JS, Rosenbaum DP, Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet 2002;41:517-23
   PubMed Web of Science ®Google Scholar
• Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf 2003;26:1093-115
   PubMedGoogle Scholar
• Burke SK, Amin NS, Incerti C, Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. J Clin Pharmacol 2001;41:199-205
   PubMed Web of Science ®Google Scholar
• Slatopolsky EA, Burke SA, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999;55:299-307
   PubMed Web of Science ®Google Scholar
• Bleyer AJ, Burke SK, Dillon M, A comparison of the calcium-free binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33:694-701
   PubMed Web of Science ®Google Scholar
• De Santo N, Frangiosa A, Anastasio P, Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 1999;19(Suppl 9):S108-14
   Google Scholar
• Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant 1997;12:961-4
   PubMed Web of Science ®Google Scholar
• Wrong O, Harland C. Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure. Nephron Physiol 2007;107:17-33
   Google Scholar
• Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binder lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci 2007;96:2818-27
   PubMed Web of Science ®Google Scholar
• Braunlin W, Zhorov E, Guo A, Bile acid binding to sevelamer hydrochloride. Kidney Int 2002;62:611-19
   PubMed Web of Science ®Google Scholar
• Wilkes BM, Reiner D, Kern M, Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol 1998;50:381-6
   PubMed Web of Science ®Google Scholar
• Burke SK, Amin NS, Incerti C, Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmocokinetics of two commonly used antihypertensives in healthy volunteers. J Clin Pharmacol 2001;41:199-205
   PubMed Web of Science ®Google Scholar
• Kays MB, Overholser BR, Mueller BA, Effects of sevelamer hydrochlride and calcium acetate on the oral bioavailabitiy of ciprofloxacin. Am J Kidney Dis 2003;42:1253-9
   PubMed Web of Science ®Google Scholar
• Burke S, Amin N, Incenti C, Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. J Clin Pharmacol 2001;41:193-8
   PubMed Web of Science ®Google Scholar
• Sahai J, Healy D, Stotka J, Polk R. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol 1993;35:302-4
   PubMedGoogle Scholar
• How P, Fischer J, Arruda J, Lau A. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin J Am Soc Nephrol 2007;2:1235-40
   PubMed Web of Science ®Google Scholar
• Piepe A-K, Buhle F, Bauer S, The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant 2004;19:2630-3
   PubMedGoogle Scholar
• Genzyme Corporation. Renagel (sevelamer hydrochloride) package insert. Genzyme Corporation, Cambridge, MA; 2007
   Google Scholar
• Genzyme Corporation. Renvela (sevelamer carbonate) package insert. Genzyme Corporation, Cambridge, MA; 2007
   Google Scholar
• Navaneethan S, Palmer S, Craig J, Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54:619-37
   PubMed Web of Science ®Google Scholar
• Delmez J, Block G, Robertson J, A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68:386-91
   PubMed Web of Science ®Google Scholar
• Ketteler M, Rix M, Fan S, Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008;3:1125-30
   PubMed Web of Science ®Google Scholar
• Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nephrologists: does preventing bone disease cause arterial disease? Kidney Int 2004;66:1315-33
   PubMed Web of Science ®Google Scholar
• Block GA, Spiegel DM, Ehrlich J, Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24
   PubMed Web of Science ®Google Scholar
• Qunibi W, Moustafa M, Muenz LR, A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
   PubMed Web of Science ®Google Scholar
• Ferreira A, Frazao JM, Monier-Faugere MC, Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008;19:405-12
   PubMed Web of Science ®Google Scholar
• Asmus H-G, Braun J, Krause R, Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005;20:1653-61
   PubMed Web of Science ®Google Scholar
• Fournier A, Presne C, Oprisiu R, Sadek T. Oral calcium, sevelamer and valvular calcification in uremic patients. Nephrol Dial Transplant 2002;17:2276-7
   PubMedGoogle Scholar
• Braun J, Asmus H, Holzer H, Long-term comparison of a calcium-free phosphate binder and calcium carbonate phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004;62:104-15
   PubMed Web of Science ®Google Scholar
• Block G, Spiegel D, Ehrlich J, Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24
   PubMed Web of Science ®Google Scholar
• Barreto DV, Barreto F de C, de Carvalho AB, Phosphate binder impact on bone remodeling and coronary calcification – results from the BRiC study. Nephrol Clin Pract 2008;110:c273-83
   PubMed Web of Science ®Google Scholar
• Qunibi W, Moustafa M, Muenz L, 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65
   PubMed Web of Science ®Google Scholar
• Floege J. Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them? Nephrol Dial Transplant 2008;23:3050-2
   PubMed Web of Science ®Google Scholar
• Russo D, Miranda I, Ruocco C, The progression of coronary calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007;72:1255-61
   PubMed Web of Science ®Google Scholar
• Bailie GR, Massry SG. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview. Pharmacotherapy 2005;25:1687-707
   PubMed Web of Science ®Google Scholar
• Raggi P, James G, Burke SK, Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005;20:764-72
   PubMedGoogle Scholar
• Ferreira A, Frazao JM, Monier-Faugere MC, Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008;19:405-12
   PubMed Web of Science ®Google Scholar
• Iwata Y, Wada T, Yokoyama H, Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels. Intern Med 2007;46:447-52
   PubMedGoogle Scholar
• Mathew S, Lund R, Strebeck F, Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007;18:122-30
   PubMedGoogle Scholar
• Chertow GM, Raggi P, Chasan-Taber S, Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96
   PubMed Web of Science ®Google Scholar
• Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004;13:134-41
   PubMed Web of Science ®Google Scholar
• Ferramosca E, Burke S, Chasan-Taber S, Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005;149:820-5
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, Marz W, Atorvastatin in patients with type 2 diabetes undergoing hemodialysis. N Engl J Med 2005;353:238-48
   PubMed Web of Science ®Google Scholar
• Fellstrom BC, Jardine AG, Schmieder RE, Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407
   PubMed Web of Science ®Google Scholar
• Marrs JC, Saseen JJ. Effects of lipid-lowering therapy on cardiovascular events in patients with end-stage renale disease requiring hemodialysis. Pharmacotherapy 2010;30:823-9
   PubMedGoogle Scholar
• Caglar K, Yilmaz M, Saglam M, Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008;3:61-8
   PubMed Web of Science ®Google Scholar
• Suki W, Zabaneh R, Cngiano J, Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7
   PubMed Web of Science ®Google Scholar
• Panichi V, Bigazzi R, Paoletti S, Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCAVID study. J Nephrol 2010;23(5):556-62
   PubMedGoogle Scholar
• St Peter WL, Fan O, Weinhandl E, Liu J. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for medicare & medicaid services data. Clin J Am Soc Nephrol 2009;4:1954-61
   PubMed Web of Science ®Google Scholar
• Fan S, Ross C, Mitra S, A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 2009;24:3794-9
   PubMed Web of Science ®Google Scholar
• Delmez J, Block G, Robertson J, A randomized, double-blind crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68:386-91
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Scott LJ, Cvetkovic RS, Plosker GL. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs 2008;68:85-104
   PubMed Web of Science ®Google Scholar
• Wrong O, Harland C. Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure. Nephron Physiol 2007;107:17-33
   Google Scholar
• De Santo N, Frangiosa A, Anastasio P, Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006;19(Suppl 9):S108-14
   PubMedGoogle Scholar
• Oka Y, Miyazaki M, Takatsu S, Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. Ther Apher Dial 2007;11:107-13
   PubMed Web of Science ®Google Scholar
• Sonikian MA, Pani IT, Iliopoulos AN, Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005;27:143-7
   PubMed Web of Science ®Google Scholar
• Page D, Knoll G. Peritoneal dialysis patients using sevelamer do not present the acidosis problems that hemodialysis patients do. Adv Perit Dial 2005;21:185-7
   PubMedGoogle Scholar
• Fan S, Ross C, Mitra S, A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 2009;24:3794-9
   PubMed Web of Science ®Google Scholar
• Cleary DJ, Matzke GR, Alexander ACM, Medication knowledge and compliance among patients receiving long term dialysis. Am J Health Syst Pharm 1995;52:1895-900
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Tonelli M, Wiebe N, Culleton B, Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007;22:2856-66
   PubMed Web of Science ®Google Scholar
• Jamal S, Fitchett D, Lok C, The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 2009;24:3168-74
   PubMed Web of Science ®Google Scholar
• Manns B, Klarenbach S, Lee H, Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007;22:2867-78
   PubMed Web of Science ®Google Scholar
• Oliveira R, Cancela A, Graciolli F, Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010;5:286-91
   PubMed Web of Science ®Google Scholar
• Larsson T. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol Dial Transplant 2010;25:1376-81
   PubMedGoogle Scholar